c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial
oleh: Robert D. Morgan, Cristina Ferreras, Isabel Peset, Egle Avizienyte, Andrew G. Renehan, Richard J. Edmondson, Alexander D. Murphy, Shibani Nicum, Thomas Van Brussel, Andrew R. Clamp, Diether Lambrechts, Cong Zhou, Gordon C. Jayson
| Format: | Article |
|---|---|
| Diterbitkan: | BMC 2022-02-01 |
Deskripsi
Highlights Tissue microarrays and germline DNA from women recruited to the phase 3 trial, ICON7, underwent quantitative immunofluorescence for c-MET/VEGFR-2 co-expression and genetic sequencing for single nucleotide polymorphisms (SNPs) VEGF-pathway genes. High c-MET/VEGFR-2 co-localisation on tumour tissue independently predicted worse survival in bevacizumab-treated epithelial ovarian cancer. The VEGFR-2 rs2305945 SNPs also independently predict worse survival in bevacizumab-treated epithelial ovarian cancer.